Benzinga

MAY 19, 2023

("Creative Realities," "CRI," or the "Company") (NASDAQ: CREX , CREXW)) received a revised proposal (the "Revised Proposal") from Pegasus Capital Advisors, L.P., per share in cash (adjusted for the Company's 1-for-3 reverse stock split) effected March 27, 2023. per share in cash.

40

40

Benzinga

OCTOBER 17, 2022

17, 2022 (GLOBE NEWSWIRE) -- Pegasus Merger Co. the "Company"), an affiliate of certain investment funds managed by affiliates of Apollo Global Management, Inc., Total Consideration (1)(2)(3). NEW YORK, Oct. New York City time, on October 17, 2022 to 5:00 p.m., Tender Consideration(1). Early Participation Premium(1)(2).

Finance 40

Finance 40

Benzinga

SEPTEMBER 28, 2022

27, 2022 (GLOBE NEWSWIRE) -- Pegasus Merger Co. the "Company"), an affiliate of certain investment funds managed by affiliates of Apollo Global Management, Inc., Total Consideration (1)(2)(3). NEW YORK, Sept. New York City time, on September 27, 2022 to 5:00 p.m., Tender Consideration(1). Early Participation Premium(1)(2).

Finance 40

Finance 40

Benzinga

SEPTEMBER 7, 2022

07, 2022 (GLOBE NEWSWIRE) -- Pegasus Merger Co. the "Company"), an affiliate of certain investment funds managed by affiliates of Apollo Global Management, Inc., Total Consideration (1)(2)(3). NEW YORK, Sept. New York City time, on September 7, 2022 to 5:00 p.m., Tender Consideration(1). Early Participation Premium(1)(2).

Finance 40

Finance 40

Benzinga

SEPTEMBER 29, 2023

The business combination is being implemented pursuant to the Agreement and Plan of Merger dated March 13, 2023, by and among Mobiv, SRIVARU, and Pegasus Merger Sub Inc., In order to effectively withdraw their redemption, public stockholders need to submit their redemption withdrawal by 3:00 pm Eastern Time on the day prior to the closing.

Marketability 40

Marketability Technology 40

Benzinga

MARCH 5, 2024

March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX ), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc. By combining chemotherapy with immunotherapy strategies, the merged company aims to develop cutting-edge solutions for cancer patients.

Alpha 40

Alpha Equity Technology Marketability 40

Benzinga

MARCH 5, 2024

March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX ), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc. By combining chemotherapy with immunotherapy strategies, the merged company aims to develop cutting-edge solutions for cancer patients.

Alpha 40

Alpha Equity Technology Marketability 40